Email updates

Keep up to date with the latest news and content from Journal of Cheminformatics and Chemistry Central.

This article is part of the supplement: 8th German Conference on Chemoinformatics: 26 CIC-Workshop

Open Access Poster presentation

Ligand-based and structure-based design of novel histone demethylase inhibitors

Luca Carlino1*, Martin Leo Schmitt2, Manfred Jung2 and Wolfgang Sippl1

Author Affiliations

1 Institut für Pharmazeutische Chemie, Martin-Luther-Universität Halle-Wittenberg, Halle/Saale 06120, Germany

2 Institut für Pharmazeutische Wissenschaften, Albert-Ludwigs-Universität Freiburg, Freiburg, 79104, Germany

For all author emails, please log on.

Journal of Cheminformatics 2013, 5(Suppl 1):P41  doi:10.1186/1758-2946-5-S1-P41


The electronic version of this article is the complete one and can be found online at: http://www.jcheminf.com/content/5/S1/P41


Published:22 March 2013

© 2013 Carlino et al.; licensee BioMed Central Ltd.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Poster presentation

The genetic information in eukaryotic cells is organized in a specific structure called chromatin. The basic unit of chromatin is the nucleosome, which consist of four histone proteins and ~147 bp of DNA [1]. The N-terminal tails of these proteins contain sited for post-translational modifications directly linked to gene expression. The modifications include acetylation, methylation, phosphorylation, ubiquitinylation, sumoylation and ribosylation. Specific enzymes mediate each modification. LSD1 (Lysine Specific Demethylase I) is one of the histone demethylases, which removes one methyl group from mono- or di-methylated lysine residue. It has recently been demonstrated that androgen receptor (AR)-LSD1 complex demethylates a repressive histone mark (H3K9) promoting genes activation [2]. Experimental data show, also, that LSD1 is strongly expressed in prostate cancers [3]. For these reasons, specific modulation of LSD1 might be a promising therapeutic strategy in tissues where AR has a key physiological role. LSD1 is a flavin-dependent amine oxidase, which shares sequence identity with other flavin dependent amine oxidases like monoamine oxidase (MAO), and polyamine oxidase (PAO). After we analyzed structural differences and similarities among these enzymes several docking studies were evaluated using the available crystal structures of LSD1 and the related oxidases to discover novel LSD1 inhibitors. For the evaluation studies we selected different ligand data sets containing known inhibitors of MAO and PAO. The docking setup that showed the highest accuracy and enrichment factors was selected for virtual screening of LSD1 inhibitors. Preliminary biological data were obtained and will be discussed in the context of the target structure.

References

  1. Luger K, Mäder AW, Richmond RK, Sargent TF, Richmond TJ: Crystal structure of the nucleosome core particle at 2.8 A resolution.

    Nature 1997, 389:251-260. PubMed Abstract | Publisher Full Text OpenURL

  2. Metzger E, Wissmann M, Yin N, Müller JM, Schneider R, Peters AHFM, Günther T, Buettner R, Schüle R: LSD1 demethylates repressive histone marks to promote androgen-receptor-dependent transcription.

    Nature 2005, 437:436-439. PubMed Abstract | Publisher Full Text OpenURL

  3. Kahl P, Gullotti L, Heukamp LC, Wolf S, Friedrichs N, Vorreuther R, Solleder G, Bastian PJ, Ellinger J, Metzger E, Schüle R, Buettner R: Androgen receptor coactivators lysine-specific histone demethylase 1 and four and a half LIM domain protein 2 predict risk of prostate cancer recurrence.

    Recurr Cancer Res 2006, 66:11341-11347. Publisher Full Text OpenURL